Managing interactions between cognitive enhancers and other psychotropics

@article{Tang2017ManagingIB,
  title={Managing interactions between cognitive enhancers and other psychotropics},
  author={S. Tang and Wayne H Tang and B. Leonard},
  journal={International Clinical Psychopharmacology},
  year={2017},
  volume={32},
  pages={175–183}
}
  • S. Tang, Wayne H Tang, B. Leonard
  • Published 2017
  • Medicine
  • International Clinical Psychopharmacology
    • Polypharmacy is common in psychiatry. Usage of cognitive enhancers is increasing in the psychiatric population. Many clinicians are not familiar with these new psychoactive compounds. This paper reviews the potential drug–drug interactions when these cognitive enhancers are used together with psychotropic drugs and their confounding effects on diagnosis and clinical management. 
    View on Wolters Kluwer
    ncbi.nlm.nih.gov

    References

    SHOWING 1-10 OF 130 REFERENCES
    Patients on psychotropic medications and herbal supplement combinations: clinical considerations
    • 4
    Additional Evidence of the Abuse Potential of Quetiapine
    • 49
    Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting
    • 40
    Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.
    • C. Andrade
    • Medicine, Psychology
    • The Journal of clinical psychiatry
    • 2015
    • 5
    • PDF
    Caffeine-Induced Psychosis
    • 53
    A review of the effects of modafinil on cognition in schizophrenia.
    • 52
    • PDF
    Caffeine-induced psychiatric manifestations: a review
    • 27
    Caffeine and psychiatric symptoms: a review.
    • 79
    Drug interactions with newer antidepressants: role of human cytochromes P450.
    • 152
    Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review
    • 22